In 2002, Bayer Biological Products instituted the Bayer Hemophilia Awards Program with the following mission:

The Bayer Hemophilia Awards Program supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training, and other hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide.

Who We Are

Bayer is a worldwide chemical and pharmaceutical company with a 138-year history, a solid reputation for developing groundbreaking solutions to a variety of diseases and disorders, and a steadfast commitment to funding the research endeavors of our partners in the medical community.

Bayer Healthcare Pharmaceuticals is a division of Bayer HealthCare, LLC. For more than 60 years, scientists and researchers at Bayer Healthcare Pharmaceuticals have been dedicated to developing and producing novel treatments that extend and enhance the lives of patients who suffer from life-threatening diseases such as hemophilia, alpha1-antitrypsin deficiency, and a variety of immune diseases.

Bayer envisions the Hemophilia Awards Program as a step toward making the dream of hemophilia cures and improved treatments a reality.

The Bayer Hemophilia Awards Program demonstrates our commitment to the global bleeding disorders community and to advancing the state of the art of hemophilia care.